Power of 3

Kevin Reed. Photo courtesy of Stony Brook University

By Daniel Dunaief

Rain, rain go away, come again some other day.

The days of wishing rain away have long since passed, amid the reality of a wetter world, particularly during hurricanes in the North Atlantic.

In a recent study published in the journal Nature Communications, Kevin Reed, Associate Professor and Associate Dean of Research at the School of Marine and Atmospheric Sciences at Stony Brook University, compared how wet the hurricanes that tore through the North Atlantic in 2020 would have been prior to the Industrial Revolution and global warming.

Reed determined that these storms had 10 percent more rain than they would have if they occurred in 1850, before the release of fossil fuels and greenhouse gases that have increased the average temperature on the planet by one degree Celsius.

The study is a “wake up call to the fact that hurricane seasons have changed and will continue to change,” said Reed. More warming means more rainfall. That, he added, is important when planners consider making improvements to infrastructure and providing natural barriers to flooding.

While 10 percent may not seem like an enormous amount of rain on a day of light drizzle and small puddles, it represents significant rain amid torrential downpours. That much additional rain can be half an inch or more of rain, said Reed. Much of the year, Long Island may not get half an inch a day, on top of an already extreme event, he added.

“It could be the difference between certain infrastructure failing, a basement flooding” and other water-generated problems, he said. The range of increased rain during hurricanes in 2020 due to global warming were as low as 5 percent and as high as 15 percent.

While policy makers have been urging countries to reach the Paris Climate Accord’s goal of limiting global warming to 2 degrees Celsius above the temperature from 1850, the pre-Industrial Revolution, studies like this suggest that the world such as it is today has already experienced the effects of warming.

“This is another data point for understanding that climate change is a not only a challenge for the future,” Reed said. It’s not this “end of the century problem that we have time to figure out. The Earth has already warmed by over 1 degrees” which is changing the hurricane season and is also impacting other severe weather events, like the heatwave in the Pacific Northwest in 2021. That heatwave killed over 100 people in the state of Washington.

Even being successful in limiting the increase to 2 degrees will create further increases in rainfall from hurricanes, Reed added. As with any global warming research, this study may also get pushback from groups skeptical of the impact of fossil fuel use and more carbon dioxide in the atmosphere.

Reed contends that this research is one of numerous studies that have come to similar conclusions about the impact of climate change on weather patterns, including hurricanes.

“Researchers from around the world are finding similar signals,” Reed said. “This is one example that is consistent with dozens of other work that has found similar results.”

Amid more warming, hurricane seasons have already changed, which is a trend that will continue, he predicted.

Even on a shorter-term scale, Hurricane Sandy, which devastated the Northeast with heavy rain, wind and flooding, would likely have had more rainfall if the same conditions existed just eight years later, Reed added.

Reed was pleased that Nature Communications shared the paper with its diverse scientific and public policy audience.

“The general community feels like this type of research is important enough to a broad set of [society]” to appear in a high-profile journal, he said. “This shows, to some extent, the fact that the community and society at large [appreciates] that trying to understand the impact of climate change on our weather is important well beyond the domain of scientists like myself, who focus on hurricanes.”

Indeed, this kind of analysis and modeling could and should inform public policy that affects planning for the growth and resilience of infrastructure.

Study origins

The researchers involved in this study decided to compare how the 2020 season would have looked during cooler temperatures fairly quickly after the season ended.

The 2020 season was the most active on record, with 30 named storms generating heavy rains, storm surges and winds. The total damage from those storms was estimated at about $40 billion.

While the global surface temperature has increased 1 degree Celsius since 1850, sea surface temperatures in the North Atlantic basin have risen 0.4 to 0.9 degrees Celsius during the 2020 season.

Reed and his co-authors took some time to discuss the best analysis to use. It took them about four months to put the data together and run over 2,500 model simulations.

“This is a much more computationally intensive project than previous work,” Reed said. The most important variables that the scientists altered were temperature and moisture.

As for the next steps, Reed said he would continue to refine the methodology to explore other impacts of climate change on the intensity of storms, their trajectory, and their speed.

Reed suggested considering the 10 percent increase in rain caused by global warming during hurricanes through another perspective. “If you walked into your boss’s office tomorrow and your boss said, ‘I want to give you a 10 percent raise,’ you’d be ecstatic,” he said. “That’s a significant amount.”

Ecstatic, however, isn’t how commuters, homeowners, and business leaders feel when more even more rain comes amid a soaking storm.

Mehdi Damaghi. Photo from Stony Brook Hospital

By Daniel Dunaief

Do the birds on the Galapagos Islands, with their unique coloration, differently shaped beaks and specific nesting places, have anything to do with the cancer cells that alter the course of human lives?

For Mehdi Damaghi, Assistant Professor in the Department of Pathology at the Renaissance School of Medicine at Stony Brook University, the answer is a resounding, “Yes.”

Damaghi uses the same principles of evolutionary biology to understand how cancer, which resides within human genes, works to adapt, as it tries to win the battle to survive.

“What we try to understand is the Darwinian principals of cancer,” said Damaghi. Cancer “adapts and reprograms themselves” to their environment to survive.

Damaghi, who arrived at Stony Brook four months ago from Moffitt Cancer Center, plans to address numerous questions related to cancer. He recently received a $4 million grant from the Physical Science in Oncology program (PSON) through the National Institutes of Health/ National Cancer Institute. Working with cancer biologists, clinicians, and computational scientists, he plans to define and understand cancer’s fitness.

“We are trying to study the core evolution of cancer cells and the normal stroma around them,” said Damaghi. “We are looking at the evolution of the tumor and some of the host cells.”

Cancer biologists are trying to build mathematical and theoretical models to explore the playbook cancer uses when confronted with threats, either in the form of a body’s natural defenses against it or from therapies against which it can, and often does, develop resistance.

Treating cancer could involve using adaptive therapy, which could enable people to control and live with cancer longer, Damaghi suggested.

In studying cancer’s phenotype, or the way the disease is expressed and survives, he hopes to understand factors in the microenvironment. Many cancers, he reasons, become more problematic as people age. Indeed, centuries ago, cancer wasn’t as prevalent as it is today in part because life expectancy was shorter.

Damaghi also has an evolutionary model to explore metastasis, in which cancer spreads from one organ or system to other parts of the body. He is looking at the earliest stages of breast cancer, to see what factors some of these cancers need or take from the environment that enables them not only to develop into breast cancer, but also to spread to other systems.

Through the microenvironment, he is looking for biomarkers that might signal a potential tumor development and metastasis long before a person shows signs of an aggressive form of the disease.

“We look at the tumor as a part of a whole ecosystem that can have different niches and habitats,” he said. “Some can be hypoxic and oxidative, and others can be like a desert on Earth, where not much grows and then cancer evolves.”

Damaghi challenges cells in a culture or organoids, which are miniature, three-dimensional live models of human cells, with different microenvironmental conditions to see how they respond. He exposes them to hormones, immune cells, and hypoxic conditions.

“We try to understand what is the adaptation mechanism of cancer to this new microenvironment and how can we push them back to the normal phenotype,” he said.

Like other scientists, Damaghi has demonstrated that many of these cancer cells use sugar. Removing sugar caused some of the cancer to die.

Increasing the survival for patients could involve knowing what kinds of micro-environments cancer uses and in what order. Deprived of sugars, some cancers might turn to amino acids, dairy or other sources of food and energy.

Damaghi thinks researchers and, eventually, doctors, will have to approach cancer as a system, which might have a patient-specific fingerprint that can indicate the resources the disease is using and the progression through its various diseased stages.

Choosing Stony Brook

Damaghi appreciates the depth of talent in cancer sciences at Stony Brook University. He cited the work of Laufer Center Director Ken Dill and Cancer Center Director Yusuf Hannun. He also suggested that the Pathology Department, headed by Ken Shroyer, was “very strong.”

For their part, leaders at Stony Brook were pleased to welcome, and collaborate with, Damaghi. Hannun suggested Stony Brook recruited Damaghi because his research “bridges what we do in breast cancer and informatics.”

Shroyer, meanwhile, has already started collaborating with Damaghi and wrote that his new colleague’s focus on breast cancer “overlaps with my focus on pancreatic cancer.”

To conduct his research, Damaghi plans to look at cells in combination by using digital pathology, which can help reveal tumor ecosystems and niches.

He also appreciated the work of Joel Saltz, the Founding Chair in the Department of Biomedical Informatics. “In the fight against cancer, we all need to unite against this nasty disease,” Damaghi said. “From looking at it at different angles, we can understand it first and then design a plan to defeat it.”

Originally from Tehran, Iran, Damaghi is the oldest of five brothers. He said his parents encouraged them to explore their curiosity.

Damaghi, whose wife Narges and two daughters Elissa and Emilia are still in Tampa and hope to join him before long, has hit the ground running at Stony Brook, where he has hired three postdoctoral researchers, a lab manager, four PhD students, two master’s candidates, and three undergraduates.

Damaghi is inspired to conduct cancer research in part because of losses in his family. Two grandparents died from cancer, his aunt has breast cancer, and his cousin, who had cancer when he was 16, fought through the disease and is a survivor for 20 years.

Damaghi bicycles and plays sports including soccer. He also enjoys cooking and said his guests appreciate his Persian kebobs.

As for his arrival in Stony Brook, he said it was “the best option for me. It’s a great package and has everything I need.”

Above, from left, CSHL Associate Professor Steven Shea, Yunyao Xie, a former postdoctoral researcher in Shea’s lab, and Roman Dvorkin at work. Photo from CSHL

By Daniel Dunaief

The black box has a blue spot.

Often considered so mysterious that it has been called “the black box,” the brain has a small cluster of cells called the locus coeruleus (LC), or blue spot because it appears blue.

The LC is the predominant source of the neurotransmitter noradrenaline, which plays numerous roles, including triggering the “fight or flight” response, sleep/wake regulation and memory.

Recently, Cold Spring Harbor Laboratory Associate Professor Stephen Shea and his post doctoral researcher Roman Dvorkin demonstrated that the LC was involved in normal maternal social behavior. In the publication Journal of Neuroscience, they demonstrated that surrogate mothers had a spike in this neurotransmitter just at the time when they retrieved young pups that had rolled out of the nest.

“Most of the research on noradrenaline and the LC has been involved in non-social behavior,” said Shea. Researchers have recorded it extensively during “cognitive tasks and memory formation.”

The evidence for its involvement in social behaviors has been more indirect. With the exception of a study 35 years ago that made a few recordings in cats, the current research is the “first time anyone has recorded” the LC during a more normal social behavior, Shea said.

Research on this blue spot could prove valuable in connection with understanding and treating a wide range of diseases and disorders. Noradrenaline (NA) is “one of the systems that is disturbed in anxiety and depression,” Dvorkin said. It also may be involved in other diseases, like autism. Scientists have conducted research on the LC and ADHD, Parkinson’s disease and Alzheimer’s disease, Dvorkin explained.

Some studies have also linked Rett syndrome, for example, which is a rare inherited genetic disorder that affects mostly girls and can alter the ability to speak, walk and eat, to lower levels of noradrenaline.

“There’s evidence that the LC has pathology in Mecp2 mice,” said Shea, referring to a gene traced to Rett. “We are working on that directly.”

Researchers believe studying the structure of the LC could lead to diagnostics and therapeutics for some of these diseases. Dvorkin suggested that this kind of research is “important to see how it works under normal, awake conditions.”

Monitoring the release of this neurotransmitter during a typical social behavior among female mice provides a context-connected understanding of its potential role.

“When people are studying this, they often use investigator-contrived tasks,” Shea said. “This is the system that preexisted for mice to use for other purposes.”

Shea has done earlier work with the LC, particularly as the sense of smell is so prominent in social interactions for mice. He demonstrated that anesthetized mice exposed to the scent of an unfamiliar mouse react as if they have a familiarity with the mouse. 

She believes the LC initiates sensory plasticity or sensory learning. NA can affect the sensory responses in parts of the brain that carry information, creating a stored memory. While his extensive work offers some clues about the role of the LC in mice, all vertebrates have the LC in their brain stems, including humans.

Shea said other research has demonstrated the involvement of the LC in cognitive tasks and memory formation, including during periods of sleep and wakefulness.

Blocking the release of noradrenaline is challenging in part because it is compact and the cells in the brain interact with so many of their neighbors, which makes turning on or off a specific signal from one region especially challenging.

At the University of Washington, Richard D. Palmiter and S.A. Thomas published a visible and definitive paper in 1997 in the journal Cell that brought the LC to other researcher’s attention.

These researchers created complete knockout mice, where they found that rodents lacking noradrenaline were “really bad mothers,” according to Shea.

In their research, Dvorkin and Shea used optogenetics and chemogenetics to inactivate the LC and the release of noradrenaline.

Future experiments

Below, a mouse retrieving a pup that has rolled out of its nest. Photo by Roman Dvorkin

The next step in this research could involve understanding the relative importance of the signal from the LC and noradrenaline.

In typical life settings, mice and other vertebrates confront competing signals, in which a pup rolls out of the nest at the same time that one of their many predators, like a hawk or other bird is circling overhead.

“That could be a next step” in this research, said Dvorkin.

Dvorkin believes it is possible to increase or decrease the threat level for mice gradually, in part because mice learn quickly when the threat is not real or what to avoid if the threat is too risky.

Shea is also looking more closely at courtship behavior.

The LC could be involved in sexual selection and in dominance hierarchies, enhancing the aggressive behavior of alpha males towards less dominant males. 

“We see big signals associated with events in courtship, including when the female and male begin to mate,” said Shea.

A resident of East Northport, Dvorkin lives with his wife Paolina and their nine year-old son Adam, who is in third grade at Pulaski Road School.

Originally from Afula in northern Israel, Dvorkin has been working in Shea’s lab for over five years. Outside the lab, he enjoys spending time with his family, taking pictures, and swimming at the JCC.

Dvorkin has enjoyed his work at CSHL, which he described as a “great experience in a beautiful place,” where he can appreciate the quiet and where he has received considerable support.

In the future, he’d like to apply his expertise in working on neuronal cell cultures and behaving animals to address translative questions, such as neurodegeneration.

Heather Lynch Photo courtesy of Rolf Sjogren/ National Geographic

By Daniel Dunaief

To borrow from the Pink song in the movie Happy Feet, the Pew Trusts for Marine Conservation recently delivered “something good” to Stony Brook University’s Heather Lynch. 

Endowed chair for ecology and evolution at Stony Brook University’s Institute for Advanced Computational Science, Lynch was selected as one of six Pew Fellows in Marine Conservation.

Lynch, who uses a host of tools including physics and satellite imagery to study penguin populations in Antarctica and associated island groups including in South Georgia and the South Sandwich Islands, is one of six international recipients of the 2022 fellowship, which includes $150,000 over three years, and is a mid-career prize.

Lynch plans to use the funds to chronicle species health in the macaroni and king penguin and forecast risks to Antarctica’s penguin populations.

Lynch’s work is “really important,” said Claire Christian, Executive Director of the Antarctic and Southern Ocean Coalition (ASOC), who nominated Lynch for the fellowship. Lynch provides the kind of information “we need to make effective decisions about protecting Antarctica.”

Christian, who has known Lynch for about five years, said Lynch’s consistent commitment helps “provide a broader picture of what’s happening down there over a longer time frame.”

Christian is particularly pleased that Lynch’s work in the Antarctic brings necessary attention to the region, even though “it’s far away at the end of the world,” she said. “People understand that [the Antarctic] is worth investing time and resources into studying.”

The Pew Fellows Program in Marine Conservation provides recipients with an opportunity to interact with other winners and alumni. This year, the Pew Trust received over 50 nominees.

Past honorees at Stony Brook University include Endowed Professor of Ocean Conservation Sciences at the School of Marine and Atmospheric Science Ellen Pikitch and Endowed Research Chair for Nature and Humanity Carl Safina.

Jane Lubchenco, who won a Pew Fellowship in marine conservation in the 1992, was the first woman to lead the National Oceanographic and Atmospheric Administration and is the current Deputy Director for Climate and Environment in the White House.

Rebecca Goldburg, Director of Environmental Sciences at the Pew Charitable Trusts, appreciates the mixture of high-level research Lynch produces and the application of her discoveries to conservation and added that Lynch has “outstanding scientific achievement that is well-integrated into decision making.”

Climate change

While researchers haven’t broadly chronicled the movement of macaroni penguins into the Antarctic, Lynch anticipates that climate change would draw them into the Antarctic.

“My hope is that a focus on macaroni penguin census data will illuminate their trends,” she explained in an email.

King penguins, meanwhile, have recently arrived in the Antarctic. The presence of king penguins would represent a turning point for Lynch, as they would suggest that the Antarctic is starting to show ecological similarities with the sub-Antarctic.

King penguins have attempted to breed on Elephant Island, which is about 800 miles from their typical habitat in South Georgia. While this species of penguin has traveled this distance in prior years, their decision to settle and try to raise chicks, which they haven’t successfully done, is “new and ecologically interesting,” Lynch explained.

Lynch suggested such a geographic expansion is rare because these birds are long-lived and an established pair will breed in the same location for years. Even in young individuals traveling to new territories, the rate of range shift is slow and hard to track.

“The movement of king penguins into Antarctica is exactly what would have been predicted and so it is an exciting (if, from a climate perspective, disturbing) time to be watching this all unfold,” she said.

King penguins can form large colonies, which could, over the course of a longer period of time, create competition for space with chinstraps. Lynch suggested that the region could be in the early days of an ecologically important event.

Where’s Waldo?

As for macaroni penguins, whose stories about how they got their name include one involving a sailor slang for men who dressed in bright colors, they have frequently been the “Where’s Waldo?” of what Lynch does, she said, as she encounters them by chance in a colony of another species.

She is pulling together several decades of offhand notes about her findings on macaronis to track them systematically. She believes collecting information about populations of macaroni and king penguins in Antarctica is going to be informative.

In analyzing penguin populations across species, Lynch plans to take the kind of approach portfolio managers apply when they consider where to focus their attention.

A mutual fund manager with a large percentage of the value of the fund linked to changes in the stock price of Apple would likely track the earnings of the company and its share price more closely than stocks in which she has smaller holdings or whose values don’t fluctuate much.

For penguins, Lynch suggested that scientists and conservationists may “need to understand those colonies, and there may not be that many, that contain a large percentage of the world’s population,” she said.

For a long time, researchers have focused on colonies that were easier to study because they were small and close by. “I don’t think we can justify that approach anymore,” Lynch said.

Picking penguin spots

Goldburg appreciates Lynch’s framework for penguin conservation.

Lynch will address the “key penguin colonies,” some of which are contributing disproportionately to the risk of penguin declines, Goldburg said. This approach will enable conservationists to monitor important sites because they “can’t do everything.” 

Understanding penguin populations goes beyond a simple rule that more of any population is necessarily better. Major increases or decreases should be cause for concern because they reflect shifts in the functioning of the ecosystem, she explained.

Christian is confident the work Lynch does will provide policy makers with key information.

“Her work is really important and it deserves to have a lot of visibility and funding,” Christian said. “Without understanding what’s happening to species that are living down there, we can’t” design effective strategies to protect them and their ecosystems.

Lynch provides the kind of information necessary to “make effective decisions about protecting Antarctica,” Christian added.

Dr. Henry Tannous during surgery. Photo from SBU

By Daniel Dunaief

While she hasn’t resolved the debate about two approaches to a type of heart surgery, Laurie Shroyer, Professor and Vice Chair for Research in the Department of Surgery at Stony Brook University’s Renaissance School of Medicine, has contributed considerable information over a long period of time.

Laurie Shroyer. Photo from SBU

In a recent study released in JAMA Surgery, Shroyer, who is the principal investigator and co-PIs Fred Grover and Brack Hattler of the Rocky Mountain Regional Affairs Medical Center, revealed that coronary artery bypass grafting had similar post-surgical death rates for the veterans in their study whether the surgeon used a heart-lung machine, called “on pump,” or performed the surgery without the machine, called “off pump.”

Using long-term results from 2,203 mostly men at 18 VA Centers in the Department of Veterans Affairs Randomized On/Off Bypass (ROOBY) trial, Shroyer determined that the death rate at 10 years was 34.2 percent for off-pump, compared with 31.1 percent for on-pump.

Patients typically need bypass graft surgery when they have a narrowing of their coronary arteries, which comes from fatty material accumulating in the walls of the arteries. Doctors take a part of a healthy blood vessel from the leg, wrist or elsewhere and bypass the blockage, building a detour for the blood and enabling better circulation in the heart.

Using the “off pump” procedure means doctors operate on a heart that’s still pumping blood through the body. The “on pump” procedure uses a heart lung machine to pump blood while the heart remains still.

While the results of this study don’t end the debate over whether one procedure is superior to another, doctors welcomed the data as a well-researched and detailed analysis.

“There’s always going to be this ever-last question of whether off versus on pump bypass surgery is better,” said Dr. Henry Tannous, Chief of Cardiothoracic Surgery at the Renaissance School of Medicine at Stony Brook University. “There’s always going to be very little nuances with different patients that will make us pick one or the other.”

Dr. Tannous who has performed the majority of all bypass surgeries at Stony Brook over the last five years, said the hospital offers surgeries with and without the pump. SB has doctors who specialize in each kind of bypass in case of a change in the expected procedure.

Doctors typically get a clear sense of whether a patient might benefit from on or off pump procedures before starting surgeries. In the great majority of cases, doctors perform the surgery according to their pre-planned expectations for the use of the pump.

Rarely, they convert to the other procedure based on inter operative findings that dictate the switch, Dr. Tannous explained.

Dr. Jorge Balauger, Associate Chief of Cardiothoracic Surgery and Director of Advanced Coronary Surgery, has performed 4,000 CABG procedures, including about 1,000 without the heart lung machine, or “off pump.”

In his considerable experience, he suggested that an 80-year old, who has renal or liver dysfunction and/or arteries in his or her neck that are partially blocked or had another type of comorbidity, such as something in the bone marrow, would not tolerate a heart lung machine well. A person with cirrhosis also would likely be better served with an off pump operation.

“Avoiding the heart lung machine on the older, sick patients is beneficial,” Dr. Balauger said, adding that he looks at the CABG procedure as being akin to a “tailor made suit” that has to fit the patient specifically.

In cases where patients need a second bypass procedure, Dr. Balauger also recommends off pump efforts because a second operation on pump is “way more complex” and requires “dissection of all the scar tissue around the heart, which makes it not only time consuming, but also risky.”

Dr. Henry Tannous. Photo from SBU

Dr. Tannous appreciates the perspective Shroyer brings to the discussion. “Sometimes, it’s an asset to have a researcher and statistician with a very scientifically oriented mind lead the study,” he said, adding that when surgeons meet with patients, they will discuss the use of the pump.

Dr. Baulager described the trial conducted by Shroyer as having an “excellent design” from a scientific standpoint.

He believed, however, that the study didn’t include surgeons who had sufficient expertise in off pump procedures. Dr. Baulager thought more experienced surgeons likely ensured better outcomes for off pump procedures.

One aspect of the study that was “refreshing” to Shroyer was how durable the surgical procedure is, with about 70 percent of patients who received this procedure, both on and off pump, still experiencing improvements in their pre-surgical chest pain symptoms after 10 years.

“We never expected the high proportion of patients would do so well longer term in terms of freedom from events, and in terms of symptoms,” she said. “The fact that the symptoms weren’t different between on and off pump is good news.”

After this type of study, Shroyer will work with several other trials to identify if certain sub-groups of high risk patients may have benefits from an off pump procedure.

To be sure, Shroyer cautioned that these results couldn’t be extrapolated to the general population, especially to women, as almost all of those the study followed were men.“Veterans are a unique population,” she said. “Many received cigarettes as part of their rations, and hypertension is quite high. They are a different population in terms of their [health care] complexities and their [underlying] illnesses.”

While the 10 year outcomes were similar, Shroyer found a shorter revascularization-free survival period among off pump patients. 

Dr. Tannous said this kind of study would generate considerable interest among cardiac surgeons.

“Everything [Shroyer] has written about bypass surgery from the ROOBY trials will catch any cardiac surgeon’s attention nationwide,” he said. “This paper is not any different. It has the extra long-term follow up that makes it more relevant.”

Famotidine molecule Image courtesy of Wikipedia

By Daniel Dunaief

An over-the-counter stomach-soothing medication may also relieve some of the symptoms of mild to moderate COVID-19.

Tobias Janowitz Photo courtesy of CSHL

In a study recently published in the journal Gut, Cold Spring Harbor Laboratory Assistant Professor Tobias Janowitz and a team of collaborators at CSHL and The Feinstein Institutes for Medical Research at Northwell Health demonstrated that Famotidine, the active ingredient in Pepcid, shortened the duration of symptoms for a diverse patient group of adults soon after developing COVID-19 symptoms.

In a placebo-controlled study, people taking 80 milligrams of Famotidine three times a day reported that symptoms such as headaches declined after 8.2 days, compared with 11.4 days for patients who were taking the placebo.

“We think that the results are preliminary, but encouraging,” Janowitz explained in an email. 

The research, which included 55 volunteers, may offer health care providers another tool to help treat mild to moderate cases of COVID-19. In the clinical study, the use of Famotidine helped reduce a potentially overactive inflammatory response without suppressing the immune system’s efforts to ward off the virus.

Participants in the study received Famotidine or placebo pills along with a host of instruments they could use at home to gather clinical data about themselves, including a cellular activated Apple iPad, a scale, thermometer, fitness tracker, spirometer to measure air flow in and out of the lungs and a pulse oximeter, which measured oxygen levels by taking a reading over a person’s fingernails.

The protocol for the study allowed volunteers to stay home, where they gathered results from the instruments and reported on their health and any symptoms they felt. Technicians came to the home of each volunteer on the first, seventh, 15th, and 28th days after entering the clinical trial.

Researchers and doctors involved in the analysis of the effectiveness of COVID believe this remote approach to participating in clinical trials could prove a safe and effective way to conduct research for other diseases.

“In today’s virtual world, our clinical trial strategy has significant implications for how to study new drugs in patients at home,” Dr. Kevin Tracey, president and CEO of the Feinstein Institutes, explained in a Cold Spring Harbor Laboratory news brief.

Janowitz added that other studies could also use testing protocols at home, including for other diseases. “We are looking forward to employing it to help develop better treatments for people with cancer,” which is the disease at the center of his research, he explained.

The CSHL Assistant Professor focuses on the whole body response to cancer, although many of the biological considerations are transferable to other diseases.

Pivot to COVID

According to Janowitz, “It was relatively easy for us to pivot to COVID research when it was a global area of unmet need.” 

The researchers chose Famotidine because of encouraging studies and from a case series, Janowitz explained. They also found a potential mechanism of action where Famotidine blocked the H2 receptor, which encouraged them to move to a phase 2 randomized clinical trial.

The researchers were pleased that the participants in this small trial included people from a range of ages and ethnic groups. Nearly two thirds of patients, who were 18 years and older, were from black, mixed-race or Hispanic communities.

“Patients with different ancestry may have different responses to this disease,” Janowitz explained. “It helps to learn about the generalizability of the results.”

In a CSHL news brief, Nicole Jordan-Martin, executive director for New York City Health + Hospitals, added that “accessible, safe and low-cost outpatient treatment options are a priority in our global efforts to combat COVID-19.” Northwell and New York City Health + Hospitals provided care for the communities most in need of support for New York City, she added.

The collaborators were also encouraged by their teamwork.

“Our institutions worked extremely well together to face challenges the pandemic posed, like offering digital solutions and reaching populations who struggled for access to care,” Dr. Christina Brennan, vice president of clinical research at the Feinstein Institute and co-investigator of the trial, said in the news brief. 

“From screening patients to organizing home delivery of the equipment and medication, this sets a new model for future trials and convenience for participants.”

Janowitz described the safety profile of Famotidine as “excellent” and said it “appears to have few interactions with other drugs and very few side effects in general.”

To be sure, Janowitz cautioned doctors and patients not to stock up on Famotidine before researchers conduct additional studies.

“Our trial is not conclusive and an early phase clinical trial (phase 1 or 2) is not sufficient to inform clinical practice,” he wrote.

Additionally without further study, researchers don’t know the best potential dose and dosing interval for this possible treatment. At this point, they know how long the drug stays in the blood and the strength of its binding to its receptor.

A dose of 20 milligrams per day or less may be too little to achieve an effect, but “we do not know this for certain,” Janowitz explained.

While researchers agreed that further studies were necessary to answer key questions, they believed that the results from this research could provide fodder for studies outside of the COVID world.

“It is possible that sustained inflammation contributes to illness in other contexts and changing this inflammation would be beneficial,” Janowitz wrote. “This will have to be explored separately. Importantly, the methods used in this trial are also transferrable, so we have learned a lot of important information” from this research.

Jose M. Adrover and Mikala Egeblad. Photo by Lijuan Sun

By Daniel Dunaief

Cold Spring Harbor Laboratory Professor Mikala Egeblad thought she saw something familiar at the beginning of the pandemic.

Mikala Egeblad. Photo from CSHL

Egeblad has focused on the way the immune system’s defenses can exacerbate cancer and other diseases. Specifically, she studies the way a type of white blood cell produces an abundance of neutrophil extracellular traps or NETs that can break down diseased and healthy cells indiscriminately. She thought potentially high concentrations of these NETs could have been playing a role in the worst cases of COVID.

“We got the idea that NETs were involved in COVID-19 from the early reports from China and Italy” that described how the sickest patients had severe lung damage, clotting events and damage to their kidneys, which was what she’d expect from overactive NETs, Egeblad explained in an email.

Recently, she, her post doctoral researcher Jose M. Adrover and collaborators at Weill Cornell Medical College and the Icahn School of Medicine at Mt. Sinai proved that this hypothesis had merit. They showed in hamsters infected with COVID and in mice with acute lung injuries that disabling these NETs improved the health of these rodents, which strongly suggested that NETs are playing a role in COVID-19.

“It was very exciting to go from forming a hypothesis to showing it was correct in the context of a complete new disease and within a relatively short time period,” Egeblad wrote.

Egeblad, Andover and their collaborators recently published their work in the Journal of Clinical Investigation Insight.

Importantly, reducing the NETs did not alter how much virus was in the lungs of the hamsters, which suggests that reducing NETs didn’t weaken the immune system’s response to the virus.

Additional experiments would be necessary to prove this is true for people battling the worst symptoms of COVID-19, Egeblad added.

While the research is in the early stages, it advances the understanding of the importance of NETs and offers a potential approach to treating COVID-19.

An unexpected direction

Jose Adrover. Photo from CSHL

When Adrover arrived from Spain, where he had earned his PhD from the Universidad Complutense de Madrid and had conducted research as a post doctoral fellow at the Spanish Center for Cardiovascular Research in March of 2020, he expected to do immune-related cancer research.

Within weeks, however, the world changed. Like other researchers at CSHL and around the world, Egeblad and Adrover redirected their efforts towards combating COVID.

Egeblad and Andover “were thinking about the virus and what was going on and we thought about trying to do something,” Adrover said. 

Egeblad and Adrover weren’t trying to fight the virus but rather the danger from overactive NETs in the immune system.

Finding an approved drug

Even though they were searching for a way to calm an immune system responding to a new threat, Egeblad and Adrover hoped to find a drug that was already approved.

After all, the process of developing a drug, testing its safety, and getting Food and Drug Administration approval is costly and time-consuming. 

That’s where Juliane Daßler-Plenker, also a postdoctoral fellow in Egeblad’s lab, came in. Daßler-Plenker conducted a literature search and found disulfiram, a drug approved in the 1950’s to treat alcohol use disorder. Specifically, she found a preprint reporting that disulfuram can target a key molecule in macrophages, which are another immune cell. Since the researchers knew this was important for the formation of NETs, Daßler-Plenker proposed that the lab test it.

Working with Weill Cornell Medical College and the Icahn School of Medicine at Mt. Sinai, Adrover explored the effect of disulfiram, among several other possible treatments, on NET production.

Using purified neutrophils from mice and from humans, Adrover discovered that disulfiram was the most effective treatment to block the formation of NETs.

He, Assistant Professor Robert Schwartz’s staff at Weill Cornell and Professor Benjamin tenOever at Mt. Sinai tried disulfiram on hamsters infected with SARS-Cov-2. The drug blocked net production and reduced lung injury.

The two experiments were “useful in my opinion as it strengthens our results, since we blocked NETs and injury in two independent models, one of infection and the other of sterile injury,” Adrover said. “Disulfuram worked in both models.”

More work needed

While encouraged by the results, Egeblad cautioned that this work started before the availability of vaccines. The lab is currently investigating how neutrophils in vaccinated people respond to COVID-19.

Still, this research offered potential promise for additional work on NETs with some COVID patients and with people whose battles with other diseases could involve some of the same immune-triggered damage.

“Beyond COVID, we are thinking about whether it would be possible to use disulfiram for acute respiratory distress syndrome,” Egeblad said. She thinks the research community has focused more attention on NETs.

“A lot more clinicians are aware of NETs and NETs’ role in diseases, COVID-19 and beyond,” she said. Researchers have developed an “appreciation that they are an important part of the immune response and inflammatory response.”

While researchers currently have methods to test the concentration of NETs in the blood, these tests are not standardized yet for routine clinical use. Egeblad is “sensing that there is more interest in figuring out how and when to target NETs” among companies hoping to discover treatments for COVID and other diseases.

The CSHL researcher said the initial race to gather information has proven that NETs are a potentially important target. Down the road, additional research will address a wide range of questions, including what causes some patients to develop different levels of NETs in response to infections.

Abhay Deshpande with a group of students at Stony Brook University. Photo from SBU

By Daniel Dunaief

The American Association for the Advancement of Science recently named physicist Abhay Deshpande a Fellow.

Abhay Deshpande. Photo from SBU

Deshpande, who thinks big about small matter, has distinguished himself with his discoveries, ideas, leadership, innovation, and mentorship. The Director of Electron Ion Collider Science at Brookhaven National Laboratory (BNL) and SUNY Distinguished Professor at Stony Brook University will become a fellow as part of an online ceremony on Feb. 19.

“I was really pleasantly honored” to be a part of a group that includes so many leaders in science, including actor and science advocate Alan Alda, who founded the eponymous Alan Alda Center for Communicating Science at Stony Brook, said Deshpande.

Deshpande’s collaborators and scientific colleagues said Deshpande deserved the AAAS honor, which the society has given since 1874.

“Everything [Deshpande] has been doing is advancing science,” said Haiyan Gao, Associate Laboratory Director in Nuclear and Particle Physics at BNL.

Fundamental questions

A physicist who earned his bachelor’s degree from the University of Bombay, which is now called the University of Mumbai, his Master’s degree from the Indian Institute of Technology, Kanpur and his PhD at Yale University, Deshpande has put his academic and intellectual talents to work answering fundamental questions about atoms.

In his research, Deshpande studies protons in the nucleus.

Inside protons and neutrons are quarks and gluons, which are fundamental particles. Gluons have no mass and bind the quarks together, which suggests that the mass of protons must come from quarks — except that it doesn’t.

“The surprise is that all quarks together only account for about one percent of the proton’s mass,” Deshpande explained in an email.

Researchers don’t know how the components of quarks and gluons and their energies contribute to the proton’s mass. At the same time, Deshpande wants to know about the origin of a proton’s spin. 

Quarks constitute about a quarter of a proton’s spin and gluon’s another quarter, which suggests that the remaining spin should come from their orbital angular momentum.

Deshpande never thought about the mass deficit until a few years ago because of his focus on a proton’s spin. “The same rotational motion of the quarks and gluons could not only explain the spin, but hopefully explain the mass,” Deshpande said. Such a solution to both unanswered questions would be “elegant,” he said.

EIC champion

A $2 billion Electron Ion Collider, which the Department of Energy awarded BNL in 2020, will take measurements that will study the origin of the remaining spin and mass. BNL will start building the EIC, which will take eight years to construct, in 2024.

Dmitri Kharzeev, Distinguished Professor and Director in the Center for Nuclear Theory at Stony Brook University, helped nominate Deshpande to become a AAAS fellow in part because of his work developing BNL’s EIC bid.

Deshpande “really played a major role in bringing this project to Long Island,” Kharzeev said. “It means a lot for BNL, and it also means a lot for Long Island as a whole. A lot of people will be hired to work on it.”

Kharzeev said Deshpande is the leader of the science effort at the EIC “precisely because of his status in the scientific community.”

Kharzeev said some of Deshpande’s papers are “among the highest-cited papers in experimental nuclear physics,” which is considered a reflection of the importance of the work.

Gao credited Deshpande and other key leaders in the community for preparing a “white paper which laid out the science in a very convincing and powerful way,” which helped make the EIC a reality.

In addition to Deshpande’s accomplishments as a scientist, Kharzeev lauded his colleague’s leadership. Deshpande brought together researchers from BNL and Thomas Jefferson National Accelerator Facility in Virginia, which were originally competing for the rights to build the EIC. He helps researchers “put science first and scientific politics second,” which is a “spectacular achievement,” Kharzeev said.

Throughout his career, Deshpande has sought to find complementary strengths among his colleagues.

He is the founding director of the Center for Frontiers in Nuclear Science, which is a joint operation between BNL and SBU and is passionate about sharing the excitement of research with people who work outside science.

“The science we do, the excitement we feel, needs to be talked about to high school students, to college students, to their parents” and to others, Deshpande added. 

Decision-makers in the government need to understand the benefit of the research, as well as the general public, whose taxes ultimately fund future discoveries, he said, and believes communicating science requires connecting with a range of audiences.

Science communicator

Deshpande’s colleagues gave him high marks for encouraging productive collaborations. He is “able to make very good, easy connections with people,” Gao said and is “approachable and easy to work with.”

Ciprian Gal, Assistant Research Professor at Mississippi State and Visiting Scholar at the Center for Frontiers in Nuclear Science, was a graduate student in Deshpande’s lab from 2010 to 2014

While he appreciated Deshpande’s intellectual acumen and knowledge of physics, Gal admired his mentor’s accessibility and eagerness to share his passion for science.

“He’s always very open” to everyone, Gal said, including students of any age. During Summer Sunday events at BNL, Deshpande spoke at length with middle school students and their parents.

“He instills a desire to communicate in all of us,” said Gal, who also appreciated how Deshpande made himself available to the graduate students in his lab during off hours and on weekends.

Engaging audiences

While he was interested in science during his formative years in high school in Mumbai, India, Deshpande also participated in several dramatic productions that were in Marathi, his native language. Typically, the plays tried to convey messages such as the importance of literacy and education or against blind faith and misinformation. Deshpande sees a benefit to using the techniques of drama to engage the audience.

He believes the EIC will provide precise knowledge of properties of the proton and the nuclei. “I promise that we will learn lots of new things,” he said.

Kindergarten connection

The celebrated physicist is married to Arati Deshpande, who works at American Health Pharmaceuticals. The couple, who met when they were in kindergarten and now live in Miller Place, have a daughter, Pooja, who is a graduate student at the Gillings School of Public Health in Chapel Hill, N.C. and a son, Ameesh, who is in high school.

As for his advice to students, Deshpande urges them to “identify a good scientific problem and pursue it no matter the cost or time.”

 

Jason Trelewicz Photo from SBU

By Daniel Dunaief

One day, ships in the Navy may not only last longer in the harsh environment of salt water, but some of their more complicated parts may also be easier and quicker to fix.

That’s thanks to the mechanical engineering efforts of researchers at Stony Brook University and Brookhaven National Laboratory, who have been teaming up to understand the microstructural origins of corrosion behavior of parts they produce through laser additive manufacturing into shapes with complex geometries.

The Navy is funding research at the two institutions.

Eric Dooryhee. Photo from BNL

“As you would expect you’d need near any marine environment with salt water, [the Navy] is interested in laser additive manufacturing to enable the production of parts at lower cost that have challenging geometries,” said Jason Trelewicz, Associate Professor of Materials Science and Engineering at Stony Brook University. Additionally, the Navy is hoping that such efforts can enable the production of parts with specific properties such as corrosion resistance on demand.

“If you’re out at sea and something breaks, can you make something there to replace it?” asked Trelewicz. Ideally, the Navy would like to make it possible to produce parts on demand with the same properties as those that come off a manufacturing line.

While companies are currently adopting laser additive manufacturing, which involves creating three-dimensional structures by melting and resolidfying metal powders one layer at a time with the equivalent of a laser printer, numerous challenges remain for developing properties in printed materials that align with those produced through established routes.

Additive materials, however, offer opportunities to structure products in a way that isn’t accessible through traditional techniques that create more complex geometry components, such as complex heat exchangers with internal cooling channels.

In addition to the science remaining for exploration, which is extensive, the process is driving new discoveries in novel materials containing unique microstructure-chemistry relationships and functionally graded microstructures, Trelewicz explained.

“These materials are enabling new engineering components through expanded design envelopes,” he wrote in an email.

With colleagues from BNL including Research Associate Ajith Pattammattell and Program Manager for the Hard X-ray Scattering and Spectroscopy Program Eric Dooryhee, Trelewicz published a paper recently in the journal Additive Manufacturing that explored the link between the structure of the material and its corrosive behavior for 316L stainless steel, which is a corrosion resistant metal already in wide use in the Navy.

The research looked at the atomic and microstructure of the material built in the lab of Professor Guha Manogharan at Penn State University. Working with Associate Professor Gary Halada in the Department of Material Science and Chemical Engineering, Trelewicz studied the corrosive behavior of these materials.

Often, the surface of the material went through a process called pitting, which is common in steels exposed to corrosive environments, which occurs in cars driven for years across roads salted when it snows.

The researchers wanted to understand “the connection between how the materials are laser printed, what their micro structure is and what it means for its properties,” Trelewicz said, with a specific focus on how fast the materials were printed.

While the research provided some structural and atomic clues about optimizing anti corrosive behavior, the scientists expect that further work will be necessary to build more effective material.

In his view, the next major step is understanding how these defects impact the quality of this protective film, because surface chemical processes govern corrosive behavior.

Based on their research, the rate at which the surface corrodes through laser additive manufacturing is comparable to conventional manufacturing.

Printed materials, however, are more susceptible to attack from localized corrosion, or pitting. 

At the hard x-ray nanoprobe, Pattammattel explored the structure of the material at a resolution far below the microscopic level, by looking at nonstructural details.

“It’s the only functional beamline that is below 10 nanometers,” he said. “We can also get an idea about the electronic structures by using x-ray absorption spectroscopy,” which reveals the chemical state.

Pattammattel, who joined BNL in 2018, also uses the beamline to study how lung cells in mice interact with air pollutants. He described “the excitement of contributing to science a little more” as the best part of each day.

Meanwhile, Dooryhee as involved in writing the seed grant proposal. By using the x-rays deflected by the variety of crystalline domains or grains that compose the materials, HE can interpret the material’s atomic structure by observing the diffraction angles. The discrete list of diffraction angles is a unique fingerprint of the material that relates to its long-range atomic ordering or stacking.

In this study, researchers could easily recognize the series of diffraction peaks associated with the 316L stainless steel.

Dooryhee was able to gather insight into the grain size and the grain size distribution, which enabled him to identify defects in the material. He explained that the primary variable they explored was the sweeping rate of the laser beam, which included 550, 650 and 700 millimeters per second. The faster the printing, the lower the deposited energy density.

Ultimately, Dooryhee hopes to conduct so-called in situ studies, in which he examines laser additive manufacturing as it’s occurring.

“The strength of this study was to combine several synchrotron techniques to build a complete picture of the microstructure of the [additively manufactured] material, that can then be related to its corrosion response,” he explained in an email.

Dooryhee grew up in Burgundy France, where his grandfather used to grow wine. He worked in the vineyards during the fall harvest to help pay for his university studies. Dooryhee has worked at BNL for over 12 years and appreciates the opportunity to collaborate with researchers at Stony Brook University.

Camila dos Santos. Photo courtesy of CSHL

By Daniel Dunaief

Pregnancy and lactation can alter genes in specific mammary cells, which may have implications in a defense against cancer.

In mouse models, mice that became pregnant at a young age have so-called epigenetic changes that survive for the animal life span and some of those are linked to a decrease in breast cancer.

In a recent study published in Cell Reports, Cold Spring Harbor Associate Professor Camila dos Santos and her graduate student Amritha Varshini Hanasoge Somasundara found that a protein involved in mammary cells in mice, called CD1d, boosts the immune system after a full pregnancy cycle, protecting it against breast cancer.

“Our research demonstrated that increased levels of CD1d in breast cells serve as a signal to recruit higher numbers of specialized immune cells” called natural killer T-cells, or NKT, “to come and reside within the breast tissue after pregnancy,” dos Santos explained in an email. These NKTs are part of mechanisms that reduce breast cancer risk after pregnancy.

Dos Santos would like to understand the molecular changes that occur from pregnancy and hopes one day to adapt them in the form of a vaccination or pill to decrease the risk of breast cancer.

To be sure, numerous questions about the process of using the immune system to prevent cancer remain, which means that the development of such a preventive pill requires considerable additional research.

Dos Santos has spent the last eight years developing model systems that allow her to discover pregnancy-induced changes that could lead to preventive strategies.

Enhancing the communication between epithelial and immune cells could represent a way to decrease breast cancer development and even treat cases of developed cancer.

To get to that point, dos Santos, the members of her lab, and her collaborators plan to make discoveries like this one to understand the dynamic interaction between the cascade of molecular interactions from pregnancy and the genetic and immunological reactions.

Humans have four CD1 genes, which all play a similar role in immunity. Additionally, there are several types of NKT cells, and each of them has a different immunological function, which means that any prevention or treatment that tapped into this system would need to bring the right CD1 molecule and the right NKT cells.

It is not yet clear whether enhancing CD1 signals protect women who might have a predisposition to breast cancer. Dos Santos is currently exploring this question in animals.

While dos Santos is focusing specifically on pregnancy-driven changes in the mammary gland, she acknowledged that altering CD1d levels in other organs might also decrease other types of cancer.

Dos Santos described pregnancy as being akin to turning on a light. First, during the course of gestation, pregnancy brightens that light to the top. After birth, the dimmer goes to the middle, leaving the system in a different state, which is not only more prepared for the next pregnancy but also to defend itself against alterations like cancer.

In most pregnancy mammary cells in mice, the scientists found a 10-fold increase in the abundance of NKT cells when compared to cells from an individual who had never been pregnant.

When the researchers removed the CD1d protein in mice, they found an association between the absence or low expression and the development of tumors in the breast.

Dos Santos and Hanasoge hypothesize that this protein is recruiting immune cells to monitor breast cells after pregnancy. If the epithelial cells develop cancer, the NKT cells may kill them, preventing the development and advancement of cancer.

In addition to working with mouse models of pregnancy, dos Santos is collaborating with Northwell Health to study cells from healthy women who are undergoing cosmetic surgery. They are analyzing that data, which wasn’t in this paper. 

Dos Santos is investigating several questions, including how the age at pregnancy influences breast tissue. She is creating organoids, which are three-dimensional models of breast cells that react to change in their environment

Joining a family

From left, Amritha Varshini Hanasoge Somasundara and Camila dos Santos

Amritha Varshini Hanasoge Somasundara, who has been a part of dos Santos’s lab for over two years, explained that she felt comfortable and supported instantly when she arrived. She described the atmosphere as extremely collegial and felt as if she were included in a scientific family.

Joining dos Santos’s group was “possibly the best decision I’ve ever made,” said Hanasoge. Dos Santos’s lab is a “really special place” where lab members often have lunch together and support each other’s research.

Hanasoge was drawn to Dos Santos’s mentorship and the overall lab dynamic. Scientifically, she was also interested in the immunology project, exploring NKT cells. Her main project has involved trying to characterize NKT cells further. 

Hanasoge sees plenty of opportunities to address additional questions in this field. “We don’t know if the process of lactation is causing more CD1d and increasing expression,” she said. “We are still trying to characterize what T-cell receptors are being expressed after pregnancy.”

A resident of Syosset, Hanasoge enjoys reading and said she was fascinated by science when she was growing up in Mysore, Kamataka in India. She asked her parents for a microscope when she was around seven and used it to looked at flower petals and leaves. That toy microscope, which her parents purchased from a science museum in Mumbai, is still in her parent’s house.

Hanasoge is eager to combine basic and translational work and hopes her research has a clinical benefit. She is looking forward to the next steps in her research in dos Santos’s lab.

“I learn from her every day by watching how she interacts with people she mentors, both inside the lab and out,” Hanasoge explained in an email. “Her passion and commitment to being a good mentor and her drive to ask the right questions in our research are inspiring.”